References
- Johnsen HE, Haioun C, Lugtenburg PJ, . Importance of granulocyte colony-stimulating factor prophylaxis in therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone given every 14 days for diffuse large B-cell lymphoma in routine clinical practice. Leuk Lymphoma 2012;53:979–981.
- Aapro MD, Bohlius J, Cameron DA, . 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumors. Eur J Cancer 2011;47:8–32.
- Pfreundschuh M, Schubert J, Ziepert M, . Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105–116.
- Delarue R, Tilly H, Salles G, . R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma: results of the interim analysis of the LNH03 - 6B GELA study. Blood 2009;114(Suppl. 1): Abstract 169.
- Delarue R, Tilly H, Salles G, . R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma (DLBCL): results of the second interim analysis of the LNH03 - 6B GELA study. Ann Oncol 2011;22(Suppl. 4):iv117.
- Cunningham D, Smith P, Mouncey P, . R-CHOP-14 vs. R-CHOP-21: results from a phase III trial for the treatment of newly diagnosed diffuse large B-cell non-Hodgkin lymphoma. J Clin Oncol 2011;29 (Suppl.): Abstract 504.
- Zwick C, Hartmann F, Zeynalova S, . Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia. Ann Oncol 2011;22:1872–1877.
- Pfreundschuh M, Zeynalova S, Poeschel V, . Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL) after dose-dense rituximab: results of the DENSE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Ann Oncol 2008;19(Suppl. 4):iv99.